[ad_1]
With the upcoming Dubai Expo 2020, the world’s largest exhibition, Novartis, the world’s leading pharmaceutical company, will unveil its Swiss pavilion in the Opportunity Zone in the opening month of Expo 2020 Dubai. As the world’s leading pharmaceutical company and has been ranked among the world’s top R&D investment companies, Novartis is committed to showcasing the most promising scientific frontiers, the most transformative medical innovations, and the most important healthcare needs.
In their experience exhibition, Novartis, which is constantly striving to reimagine medicine, will bring together four pillars, which will be shown to visiting guests, respected media, authorities and the public, focusing on data science and artificial intelligence, cell and gene therapy, and building trust. Society and patient communities. In the search for new drugs, Novartis uses innovative science and digital technology to create transformative treatments in areas with huge medical needs. In October, the Swiss company will showcase its four pillars of strength.
George Schrockenfors [President and Head MEA Cluster, Novartis] Commented: “With Novartis’s ongoing R&D journey, we collaborated with the Swiss Pavilion in the first month of Expo 2020 Dubai to showcase our company’s latest and most transformative innovations in the medical field. Our goals It is to adhere to the highest standards of sustainable development and ethical business practices, and to build trust with society. In the long run, this will enable us to continue to reimagine medicine, meet the needs of patients, and use innovative technologies to create transformative medical treatments .”
During Novartis’ participation in Expo 2020 Dubai, they will showcase four pillars:
Data Science and Artificial Intelligence
From the beginning, Novartis has embarked on an ambitious transformation to become a leading pharmaceutical company powered by data science and digital technology. Novartis is committed to integrating data science and digital technology into drug discovery (R&D) and health services. Artificial Intelligence (AI) is another major attribute of Novartis, and it is a useful place to innovate, experiment, and expand AI-based solutions. Together with its partners, Novartis aims to change the way they develop innovative drugs, interact with patients, healthcare providers and healthcare systems, and improve operational efficiency.
Cell and gene therapy
Novartis is advancing the research and development of new therapies in many disease areas, and establishing new technology platforms, including cell and gene therapy and radioligand therapy. Novartis is committed to the development and provision of gene therapy for patients and their families who are upset by rare and life-threatening genetic diseases. Cell and gene therapies are aimed at stopping or reversing the progression of the disease, rather than simply controlling the symptoms. These are usually one-time treatments that can alleviate the underlying cause of the disease, and they have the potential to cure certain diseases.
Build trust with society
A key pillar of Novartis’ strategy, which defines the key areas of their management of environmental, social and corporate governance topics; Novartis has assumed great responsibilities and greater opportunities to lead the world in creating positive social change and make social impact its core business Target. As part of pricing and accessing solutions, responding to global health challenges, becoming a responsible citizen, and adhering to high ethical standards, Novartis follows a comprehensive approach in these global efforts and continues to be deeply rooted in the journey of creating a culture Rooted in their daily work.
Patient community
Novartis has been committed to working with patient communities around the world to learn new ways to improve and extend people’s lives. Through cooperation, Novartis can improve patient outcomes and change medical practice. Every day, Novartis recognizes the importance of patients and caregivers, as well as their understanding of the company’s expectations, because they are committed to actively seeking and listening to the insights of the patient community and consolidating their commitment to using science-based innovations to solve some problems. promise. The most challenging health care problem in society.
Mohamed Ez Erding [President and Gulf Cluster Head, Novartis] He also said: “Because we are honored to showcase our brand attributes in our home country pavilion, Switzerland is not only the first country to confirm its participation in the 2020 Dubai World Expo, but Novartis is the first Swiss company to confirm its presence in the Swiss pavilion. The exhibition hall during this large-scale event. We are very pleased to be a private sector partner to help focus on Switzerland’s innovation and products and services to help enhance the country’s economic capacity and attractiveness as a tourist destination in the UAE-the UAE is Switzerland’s most important trading partner in the Middle East. A country of scientists passionate about natural sciences and medicine.”
Val Omran [Oncology General Manager Gulf, Novartis] He also added: “The Swiss Pavilion reflects key aspects of Swiss culture, natural beauty and innovation through a series of interactive elements and images; the country’s breathtaking scenery is the backdrop for Switzerland’s sustainable future solutions, demonstrating Swiss technology, Innovation and scientific achievements. Novartis’ exhibition will showcase our cutting-edge technology, emphasize positive impact, and hope that all our guests can have fun from it.”
Marie-Andre Gamash [Oncology Head MEA Cluster, Novartis] The comment said: “Innovation is at the core of Novartis. We will showcase the most promising scientific frontiers. We strive to interact with visiting guests and patient communities, and give back to society through education, knowledge, and meeting important healthcare needs. Patients are what we do. At the center of everything, we focus on improving and prolonging lives through continuous in-depth understanding of their needs.”
Vijay Zussi [Head of Gulf and Levant at Sandoz (a Novartis Division)] He also added: “As an organization centered on patience and science, we always have a business continuity plan ready, which is crucial for a company like ours. What’s important is that in this day and age, we focus on patients , The safety of their nursing staff and healthcare professionals who provide care, and continue to provide treatment options for our patients. As a patient-centric company with a mission to save and improve lives, we have always opened our doors to ensure No patients will be left behind in the treatment field.”
[ad_2]
Source link